106 related articles for article (PubMed ID: 33634418)
1. Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression.
Tarantino P; Curigliano G
Breast Cancer Res Treat; 2021 Apr; 186(3):885-886. PubMed ID: 33634418
[No Abstract] [Full Text] [Related]
2. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
Montemurro F; Di Cosimo S; Arpino G
Ann Oncol; 2013 Nov; 24(11):2715-24. PubMed ID: 23908178
[TBL] [Abstract][Full Text] [Related]
3. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Pizzuti L; Krasniqi E; Barchiesi G; Della Giulia M; Izzo F; Sanguineti G; Marchetti P; Mazzotta M; Giusti R; Botticelli A; Gamucci T; Natoli C; Grassadonia A; Tinari N; Iezzi L; Tomao S; Tomao F; Tonini G; Santini D; Astone A; Michelotti A; De Angelis C; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Rossi E; Cazzaniga M; Moscetti L; Omarini C; Piacentini F; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Samaritani R; Garufi C; Barni S; Mirabelli R; Sarmiento R; Veltri EM; D'Auria G; Paris I; Giotta F; Lorusso V; Cardillo F; Landucci E; Mauri M; Ficorella C; Roselli M; Adamo V; Ricciardi GRR; Russo A; Berardi R; Pistelli M; Fiorio E; Cannita K; Sini V; D'Ostilio N; Foglietta J; Greco F; Zamagni C; Garrone O; Di Cocco B; Baldini E; Livi L; Desideri I; Meattini I; Sarobba G; Del Medico P; De Tursi M; Generali D; De Maria R; Risi E; Ciliberto G; Sperduti I; Villa A; Barba M; Di Leo A; Vici P
Int J Cancer; 2020 Apr; 146(7):1917-1929. PubMed ID: 31330065
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 8 in progression of hormone-dependent early breast cancer.
Milovanovic J; Todorovic-Rakovic N; Vujasinovic T; Abu Rabi Z
J Biosci; 2017 Jun; 42(2):265-274. PubMed ID: 28569250
[No Abstract] [Full Text] [Related]
5. Adjuvant chemotherapy is not for everyone.
Henderson IC
Breast Cancer Res Treat; 2010 Aug; 123(1):159-62. PubMed ID: 20549338
[No Abstract] [Full Text] [Related]
6. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN
Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182
[TBL] [Abstract][Full Text] [Related]
7. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
Ellis MJ
J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793
[No Abstract] [Full Text] [Related]
8. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of androgen receptors in invasive breast carcinoma and its relation with estrogen receptor, progesterone receptor and Her2/neu expression.
Alshenawy HA
J Egypt Natl Canc Inst; 2012 Jun; 24(2):77-83. PubMed ID: 23582599
[TBL] [Abstract][Full Text] [Related]
10. Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer.
Abdel-Razeq H; Edaily S; Iweir S; Salam M; Saleh Y; Sughayer M; Salama O; Mustafa R; Al-Masri Y; Bater R; Taqash A
Breast Cancer Res Treat; 2021 Jan; 185(2):459-467. PubMed ID: 32974788
[TBL] [Abstract][Full Text] [Related]
11. Receptor-based predictors of response in breast cancer.
McGovern UB; Stebbing J
Future Oncol; 2009 Apr; 5(3):283-6. PubMed ID: 19374534
[No Abstract] [Full Text] [Related]
12. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.
McGuire A; Kalinina O; Holian E; Curran C; Malone CA; McLaughlin R; Lowery A; Brown JAL; Kerin MJ
Breast Cancer Res Treat; 2017 Jul; 164(1):221-229. PubMed ID: 28378298
[TBL] [Abstract][Full Text] [Related]
13. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
15. Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
van Dooijeweert C; Deckers IAG; Baas IO; van der Wall E; van Diest PJ
Breast Cancer Res Treat; 2019 Jun; 175(2):487-497. PubMed ID: 30825048
[TBL] [Abstract][Full Text] [Related]
16. Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database.
Kolarova I; Vanasek J; Dolezel M; Stuk J; Hlavka A; Dusek L; Melichar B; Büchler T; Ryska A; Prausova J; Petrakova K; Tesarova P; Petera J; Vosmik M; Horackova K; Jarkovsky J
Neoplasma; 2020 Nov; 67(6):1373-1383. PubMed ID: 32614235
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for triple-negative breast cancer: where are we?
Duffy MJ; McGowan PM; Crown J
Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
20. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
[No Abstract] [Full Text] [Related]
[Next] [New Search]
